Apogee Therapeutics (NASDAQ:APGE) Price Target Raised to $115.00 at BTIG Research

Apogee Therapeutics (NASDAQ:APGE - Free Report) had its price target lifted by BTIG Research from $100.00 to $115.00 in a research note published on Monday, MarketBeat.com reports. The firm currently has a buy rating on the stock.

A number of other brokerages also recently issued reports on APGE. Guggenheim reiterated a "buy" rating and issued a $116.00 price target on shares of Apogee Therapeutics in a report on Wednesday, July 2nd. Citigroup assumed coverage on shares of Apogee Therapeutics in a report on Thursday, March 13th. They issued a "buy" rating and a $95.00 price target for the company. Finally, Wedbush reissued an "outperform" rating and issued a $90.00 price objective on shares of Apogee Therapeutics in a research note on Tuesday, March 11th. Six analysts have rated the stock with a buy rating, According to data from MarketBeat, Apogee Therapeutics has an average rating of "Buy" and an average price target of $99.00.

Apogee Therapeutics Stock Performance

Apogee Therapeutics stock traded down $8.22 during trading hours on Monday, reaching $39.24. 6,009,087 shares of the stock were exchanged, compared to its average volume of 587,187. The stock has a market cap of $1.81 billion, a P/E ratio of -10.90 and a beta of 1.47. Apogee Therapeutics has a 52-week low of $26.20 and a 52-week high of $76.39. The firm's 50 day moving average is $40.38 and its 200 day moving average is $38.95.

Apogee Therapeutics (NASDAQ:APGE - Get Free Report) last announced its quarterly earnings data on Monday, May 12th. The company reported ($0.95) EPS for the quarter, topping analysts' consensus estimates of ($1.19) by $0.24. Equities research analysts expect that Apogee Therapeutics will post -3.09 EPS for the current fiscal year.

Insider Activity at Apogee Therapeutics

In other news, insider Carl Dambkowski sold 10,090 shares of Apogee Therapeutics stock in a transaction dated Wednesday, July 2nd. The shares were sold at an average price of $45.09, for a total transaction of $454,958.10. Following the completion of the sale, the insider directly owned 238,998 shares in the company, valued at $10,776,419.82. The trade was a 4.05% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Insiders have sold 15,540 shares of company stock worth $653,093 in the last ninety days. Insiders own 42.77% of the company's stock.

Institutional Investors Weigh In On Apogee Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. Ameriprise Financial Inc. purchased a new stake in shares of Apogee Therapeutics during the fourth quarter worth about $259,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of Apogee Therapeutics by 4.1% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,835 shares of the company's stock worth $1,078,000 after acquiring an additional 931 shares during the last quarter. Rhumbline Advisers boosted its position in shares of Apogee Therapeutics by 3.2% in the first quarter. Rhumbline Advisers now owns 54,385 shares of the company's stock worth $2,032,000 after acquiring an additional 1,665 shares during the last quarter. BNP Paribas Financial Markets acquired a new stake in shares of Apogee Therapeutics in the fourth quarter worth approximately $219,000. Finally, GAMMA Investing LLC boosted its position in shares of Apogee Therapeutics by 3,560.1% in the first quarter. GAMMA Investing LLC now owns 5,417 shares of the company's stock worth $202,000 after acquiring an additional 5,269 shares during the last quarter. 79.04% of the stock is currently owned by hedge funds and other institutional investors.

Apogee Therapeutics Company Profile

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.